TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19496943

Group type: EXPERIMENTAL
Intervention: Intraduodenal administration of 1 mg Ac min(‐1) with varying caloric densities (0.75/1.5/3 kcal min(‐1)) in a 200 mL meal.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intraduodenal administration of varying tracer delivery rates (0.5/1.0/2.5 mg Ac min(‐1)).
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intraduodenal administration of increasing Ac doses (12.5/25/50/100 mg Ac in 50 mL water).
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intraduodenal administration of 50 mg Ac in 50/100/200 mL water.
Number of subjects: 18
Study: 16796777

Group type: EXPERIMENTAL
Intervention: Continuous remission (Rc)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Discontinuous remission (Rd)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Continuous remission (Rc) among patients without cytogenetic abnormalities
Number of subjects: 254

Group type: COMPARATOR
Intervention: Discontinuous remission (Rd) among patients without cytogenetic abnormalities
Number of subjects: 254

Group type: COMPARATOR
Intervention: Hypodiploidy and deletion 13
Number of subjects: 254
Study: 15103751

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (single dose prior to cardiopulmonary bypass)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No steroid treatment (control group)
Number of subjects: 20
Study: 12169329

Group type: EXPERIMENTAL
Intervention: Vestibular evoked myogenic potentials (VEMPs)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Brainstem auditory evoked potentials (BAEPs)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Subjective visual vertical (SVV) evaluation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Saccadic eye movement recording
Number of subjects: 70
Study: 9620251

Group type: EXPERIMENTAL
Intervention: Radiotherapy (hypofractionation, 5 Gy for fraction, 3-5 doses in one week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy (conventional fractionation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy (total dose lower than 34 Gy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative chemoradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protracted infusional administration of 5FU concomitant to radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MeCCNU or Levamisole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy arm
Number of subjects: 0
Study: 7971743

Group type: EXPERIMENTAL
Intervention: 15 mg of diazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg of amitriptyline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15 mg of mirtazepine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diazepam + Mirtazepine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diazepam + Amitriptyline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 7.5 mg of zopiclone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.25 mg of triazolam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg of ethanol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hypnotic-ethanol combinations
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single drug intake
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2691677

Group type: EXPERIMENTAL
Intervention: Physical fitness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S‐adenosylmethionine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study: 4458774

Group type: EXPERIMENTAL
Intervention: Carbonated bupivacaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plain bupivacaine hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride with adrenaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: All three preparations
Number of subjects: 0
Study: 30642267

Group type: EXPERIMENTAL
Intervention: JBS3
Number of subjects: 240

Group type: COMPARATOR
Intervention: QRISK®2
Number of subjects: 240
Study: 27866449

Group type: EXPERIMENTAL
Intervention: 20% of 2 cc MgSO4 in 2 cc of isotonic saline
Number of subjects: 100

Group type: COMPARATOR
Intervention: 4 cc of isotonic saline
Number of subjects: 100
Study: 25631070

Group type: EXPERIMENTAL
Intervention: Renal denervation plus SSAHT
Number of subjects: 106

Group type: COMPARATOR
Intervention: SSAHT alone
Number of subjects: 106
Study: 23218588

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus iscador (thrice weekly until tumour progression)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus iscador
Number of subjects: 72

Group type: COMPARATOR
Intervention: Chemotherapy alone (control)
Number of subjects: 72
Study: 21576029

Group type: EXPERIMENTAL
Intervention: Dilmapimod (15 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 20092179

Group type: EXPERIMENTAL
Intervention: Autologous progenitor cells CD133+
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Leukocytic fraction of the marrow (CD34+)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 42
Study: 16443892

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle therapy
Number of subjects: 1957

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 1957

Group type: COMPARATOR
Intervention: Placebo with standard lifestyle advice
Number of subjects: 1957
Study: 15567552

Group type: EXPERIMENTAL
Intervention: venlafaxine (VLF)
Number of subjects: 52

Group type: COMPARATOR
Intervention: amitriptyline (AMT)
Number of subjects: 52
Study: 10836772

Group type: EXPERIMENTAL
Intervention: Illustrated pamphlet decision-aid
Number of subjects: 257
Study: 8841896

Group type: EXPERIMENTAL
Intervention: Sonicare toothbrush
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 60
Study: 1299491

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg/day)
Number of subjects: 1398

Group type: COMPARATOR
Intervention: Control group (no calcium supplementation)
Number of subjects: 1398
Study: 6386762

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 31495712

Group type: EXPERIMENTAL
Intervention: Ketamine (0.44 mg/kg intravenous dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Active placebo (1.7 ng/mL remifentanil)
Number of subjects: 30
Study: 31460584

Group type: EXPERIMENTAL
Intervention: NAC (1.2 g) + MTF (850-1500 mg/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: UDCA (20 mg/kg) + MTF (850-1500 mg/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: UDCA (15 mg/kg) + MTF (850-1500 mg/day)
Number of subjects: 53
Study: 28705993

Group type: EXPERIMENTAL
Intervention: HMB (3 g/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 19
Study: 26265643

Group type: EXPERIMENTAL
Intervention: AREDS formulation followed by ranibizumab
Number of subjects: 5400

Group type: COMPARATOR
Intervention: Placebo followed by ranibizumab
Number of subjects: 5400

Group type: COMPARATOR
Intervention: Placebo followed by aflibercept
Number of subjects: 5400

Group type: EXPERIMENTAL
Intervention: AREDS formulation followed by bevacizumab (monthly)
Number of subjects: 5400
Study: 23821661

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 3002

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3002
Study: 21486553

Group type: EXPERIMENTAL
Intervention: Mucosa advancement flap anoplasty
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fissurectomy
Number of subjects: 120
Study: 19735180

Group type: EXPERIMENTAL
Intervention: 0.5 g n-3 PUFAs
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 1 g n-3 PUFAs
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 2 g n-3 PUFAs
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 135
Study: 16229957

Group type: EXPERIMENTAL
Intervention: 1 mg oral dexamethasone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (age-matched healthy females), N=10
Number of subjects: 6
Study: 15108768

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) 2 mg/d
Number of subjects: 70

Group type: COMPARATOR
Intervention: Azathioprine (AZA) 2 mg/kg/d
Number of subjects: 70
Study: 10867596

Group type: EXPERIMENTAL
Intervention: Alveolar macrophages (AM) from patients with pulmonary sarcoidosis
Number of subjects: 32

Group type: COMPARATOR
Intervention: Alveolar macrophages (AM) from controls
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide-stimulated AM from patients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Monocytes from patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: Monocytes from controls
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TGF‐beta secretion from patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: TGF‐beta secretion from controls
Number of subjects: 32
Study: 9112067

Group type: EXPERIMENTAL
Intervention: Magnesium pyridoxal-5'-phosphate glutamate (MPPG) 450 mg daily for 8 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Magnesium pyridoxal-5'-phosphate glutamate (MPPG) 600 mg daily for 8 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Magnesium pyridoxal-5'-phosphate glutamate (MPPG)
Number of subjects: 23
Study: 1576857

Group type: EXPERIMENTAL
Intervention: Physical training (T = 25 pts)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (C = 24 pts)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Physical training (T)
Number of subjects: 49
Study: 2864257

Group type: EXPERIMENTAL
Intervention: Short exercise with maximal work load
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 30 min exercise with half maximal work load
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 3 x 10 min interval exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control without exercise
Number of subjects: 9
Study: 3314956

Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg twice daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29490103

Group type: EXPERIMENTAL
Intervention: Sourdough croissants (SCs)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Brewer's yeast croissants (BCs)
Number of subjects: 17
Study: 26492359

Group type: EXPERIMENTAL
Intervention: Mesh repair (trocar‐guided transobturator polypropylene and porcine dermis mesh)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Conventional repair
Number of subjects: 117
Study: 25694364

Group type: EXPERIMENTAL
Intervention: FaceSay intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study: 23689085

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 475

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 475
Study: 20629109

Group type: EXPERIMENTAL
Intervention: Gut-specific nutrients (GSNs) administered for 1 month
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gut-specific nutrients (GSNs)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17991793

Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (inspired Po(2) = 70 Torr)
Number of subjects: 5
Study: 17233322

Group type: EXPERIMENTAL
Intervention: New lacquer containing phosphonic acid methacrylate
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 12763123

Group type: EXPERIMENTAL
Intervention: Tocolytic therapy (ritodrine, indomethacin, calcium antagonists, magnesium sulphate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tocolytic therapy
Number of subjects: 0
Study: 11077646

Group type: EXPERIMENTAL
Intervention: Monthly combination injectable contraceptive
Number of subjects: 0
Study: 8828437

Group type: EXPERIMENTAL
Intervention: Maternal magnesium sulfate administered intrapartum
Number of subjects: 1189
Study: 1380429

Group type: EXPERIMENTAL
Intervention: tropisetron 5mg once daily for 5 days
Number of subjects: 78

Group type: COMPARATOR
Intervention: conventional antiemetic drugs
Number of subjects: 78
Study: 6430706

Group type: EXPERIMENTAL
Intervention: Sequential combination of chemotherapy (cisplatinum, VP‐16, adriamycin) followed by radiotherapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (cisplatinum, VP‐16, adriamycin)
Number of subjects: 57
Study: 30502929

Group type: EXPERIMENTAL
Intervention: E-cigarettes used before hospitalization
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: E-cigarettes used during hospitalization
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: E-cigarettes used after discharge
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: Current e-cigarette users at 1 month
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: Regular e-cigarette use
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: Tobacco smoking among e-cigarette users
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: Predictors of current e-cigarette use
Number of subjects: 1357
Study: 29359398

Group type: EXPERIMENTAL
Intervention: Prostascore = 2
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Prostascore = 3
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Prostascore = 4
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Prostascore = 5
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Cancer-specific survival
Number of subjects: 702
Study: 27254807

Group type: EXPERIMENTAL
Intervention: CMC-HA
Number of subjects: 365

Group type: COMPARATOR
Intervention: CMC
Number of subjects: 365
Study: 25304191

Group type: EXPERIMENTAL
Intervention: WALK 2.0 website (with Web 2.0 features)
Number of subjects: 2894

Group type: COMPARATOR
Intervention: 10,000 Steps website (with Web 1.0 features)
Number of subjects: 2894
Study: 21965126

Group type: EXPERIMENTAL
Intervention: Education + PMR (E + P)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Education (E)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) (P)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 152
Study: 19934029

Group type: EXPERIMENTAL
Intervention: LCZ696 (200-1200 mg single-dose; 50-900 mg once daily for 14 days)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: LCZ696 400 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: COMPARATOR
Intervention: Valsartan 320 mg
Number of subjects: 80
Study: 18573982

Group type: EXPERIMENTAL
Intervention: Phentolamine mesylate (0.4 mg per cartridge of local anesthetic)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 16317361

Group type: EXPERIMENTAL
Intervention: Changes in referral strategies
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: CuSum application
Number of subjects: 184
Study: 11883025

Group type: EXPERIMENTAL
Intervention: Ocytocin (2.5 IU i.v. bolus)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Misoprostol (3 tablets per os)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Control group (no preventive measures)
Number of subjects: 602
Study: 9600580

Group type: EXPERIMENTAL
Intervention: 100% oxygen with glucose
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 100% oxygen with placebo
Number of subjects: 104

Group type: COMPARATOR
Intervention: Glucose alone
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 104
Study: 7848353

Group type: EXPERIMENTAL
Intervention: Ben-u-ron 500 mg suppositories
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ben-u-ron 1000 mg suppositories
Number of subjects: 18

Group type: COMPARATOR
Intervention: Benuron tablets 500 mg
Number of subjects: 18
Study: 3073806

Group type: EXPERIMENTAL
Intervention: Terbutaline sulphate (2 puffs of 250 micrograms each, separated by approximately 15 minutes)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 10
Study: 31496537

Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound (HIFU)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Plasma Radiofrequency Ablation (PRA)
Number of subjects: 66
Study: 27822654

Group type: EXPERIMENTAL
Intervention: Biopsied embryos in RT group
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Biopsied embryos in rcp group
Number of subjects: 236
Study: 25471688

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1.5 μg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intranasal saline (placebo)
Number of subjects: 50
Study: 23748928

Group type: EXPERIMENTAL
Intervention: Housing First (HF) in scattered-site apartments
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Housing First (HF) in a congregate setting (high needs only)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Housing First (HF) in scattered-site apartments and congregate settings
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Housing First (HF) in congregate setting (high needs only)
Number of subjects: 497
Study: 21296449

Group type: EXPERIMENTAL
Intervention: 40 mg/m2 docetaxel (arm A)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 50 mg/m2 docetaxel (arm B)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 60 mg/m2 docetaxel (arm C)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 50 mg/m2 escalated to 70 mg/m2 docetaxel (arm D)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 73
Study: 19561338

Group type: EXPERIMENTAL
Intervention: Tolvaptan therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 0
Study: 17873626

Group type: EXPERIMENTAL
Intervention: OPTI-FREE RepleniSH Multi-Purpose Disinfecting Solution (regimen 1)
Number of subjects: 233

Group type: COMPARATOR
Intervention: ReNu MultiPlus Multi-Purpose Solution No Rub Formula (regimen 2)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Complete MoisturePLUS Multi-Purpose Solution (regimen 3)
Number of subjects: 233
Study: 15532340

Group type: EXPERIMENTAL
Intervention: Comprehensive HBP intervention
Number of subjects: 147

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 147
Study: 11555505

Group type: EXPERIMENTAL
Intervention: Target-flow inspiratory muscle training (IMT) at 60 to 70% SIPmax, 30 min daily, 6 days a week for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Target-flow inspiratory muscle training (IMT)
Number of subjects: 20
Study: 9777109

Group type: EXPERIMENTAL
Intervention: Computer group (CD-ROM study material)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Tutorial group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no study material)
Number of subjects: 72
Study: 7829767

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 3245867

Group type: EXPERIMENTAL
Intervention: Alcohol group (0.8 ml of 100% alcohol/kg body weight)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Placebo group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 29370781

Group type: EXPERIMENTAL
Intervention: FOLFOX plus panitumumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil (5FU) plus panitumumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G8 screening tool
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRASH score
Number of subjects: 0
Study: 26497692

Group type: EXPERIMENTAL
Intervention: Alcohol group (0.4 g/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 75
Study: 26625004

Group type: EXPERIMENTAL
Intervention: 12 weeks of paclitaxel and trastuzumab
Number of subjects: 227

Group type: COMPARATOR
Intervention: 1 year of trastuzumab
Number of subjects: 227
Study: 24024983

Group type: EXPERIMENTAL
Intervention: 0.07% cetylpyridinium chloride (CPC) mouth rinse, used three times per day
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo mouth rinse
Number of subjects: 67
Study: 21440143

Group type: EXPERIMENTAL
Intervention: Ablation plus irbesartan
Number of subjects: 83

Group type: COMPARATOR
Intervention: Ablation alone
Number of subjects: 83
Study: 19636688

Group type: EXPERIMENTAL
Intervention: Symptomatic AF episodes
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Diurnal symptomatic AF
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Nocturnal symptomatic AF
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Sensitivity and positive predictive value
Number of subjects: 79
Study: 16908795

Group type: EXPERIMENTAL
Intervention: Computer-automated feedback
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Human e-mail counseling
Number of subjects: 192

Group type: COMPARATOR
Intervention: No counseling
Number of subjects: 192
Study: 15598480

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 microg QID
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg OD
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg OD
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 11730396

Group type: EXPERIMENTAL
Intervention: Indinavir, zidovudine, and lamivudine therapy
Number of subjects: 489
Study: 7740330

Group type: EXPERIMENTAL
Intervention: Intravenous vinorelbine
Number of subjects: 0
Study: 2225410

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg q.d.
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg t.i.d.
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg and dipyridamole 75 mg t.i.d.
Number of subjects: 620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study: 103467

Group type: EXPERIMENTAL
Intervention: 225 mg or 450 mg daily of oral papaverine
Number of subjects: 11